Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP275628.RAUgNT2t08YvRtMkDL5mV_T5YYfFpxHzI3GwMA-SFfzAA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP275628.RAUgNT2t08YvRtMkDL5mV_T5YYfFpxHzI3GwMA-SFfzAA130_assertion type Assertion NP275628.RAUgNT2t08YvRtMkDL5mV_T5YYfFpxHzI3GwMA-SFfzAA130_head.
- NP275628.RAUgNT2t08YvRtMkDL5mV_T5YYfFpxHzI3GwMA-SFfzAA130_assertion description "[Therapeutic inhibitors of HER3 should be considered as part of multidrug combinations aimed at completely and rapidly disabling the HER2 network in HER2-overexpressing breast cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP275628.RAUgNT2t08YvRtMkDL5mV_T5YYfFpxHzI3GwMA-SFfzAA130_provenance.
- NP275628.RAUgNT2t08YvRtMkDL5mV_T5YYfFpxHzI3GwMA-SFfzAA130_assertion evidence source_evidence_literature NP275628.RAUgNT2t08YvRtMkDL5mV_T5YYfFpxHzI3GwMA-SFfzAA130_provenance.
- NP275628.RAUgNT2t08YvRtMkDL5mV_T5YYfFpxHzI3GwMA-SFfzAA130_assertion SIO_000772 23224399 NP275628.RAUgNT2t08YvRtMkDL5mV_T5YYfFpxHzI3GwMA-SFfzAA130_provenance.
- NP275628.RAUgNT2t08YvRtMkDL5mV_T5YYfFpxHzI3GwMA-SFfzAA130_assertion wasDerivedFrom befree-20140225 NP275628.RAUgNT2t08YvRtMkDL5mV_T5YYfFpxHzI3GwMA-SFfzAA130_provenance.
- NP275628.RAUgNT2t08YvRtMkDL5mV_T5YYfFpxHzI3GwMA-SFfzAA130_assertion wasGeneratedBy ECO_0000203 NP275628.RAUgNT2t08YvRtMkDL5mV_T5YYfFpxHzI3GwMA-SFfzAA130_provenance.